Founded in 2016 in South Korea, Genuv(지뉴브) is a clinical-stage biopharma that specializes in discovering and developing innovative therapeutics based on own platform technologies for drug discovery.
GENUV is dedicated to the discovery and development of life-transforming therapeutics for patients with debilitating diseases. To do this, we passionately endeavor to advance our own platform technologies and capitalize on our strengths in multi-disciplinary collaborations with external partners.
Our current research and development focus is on a) small molecule drugs to treat neurodegenerative diseases through neurogenesis and neural homeostasis and b) antibody drugs for immuno-oncology treatment.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Cheonggyecheon-Ro 14, Jung-Gu, 5th Fl. Nia Building,united States
- Industry
- Biotechnology
- Website
- genuv.com
- Keywords
- IP Strategy, Human antibody mouse platform, Neural stem cell based drug screening platform, MoA: Neurogenesis & Neural homeostasis, Alzheimer's Diseases, ALS, Immuno-neurology, Immuno-oncology, Antibody drug, Drug discovery & development, Platform-based drug develompent, Early stage R&D.
- HQ
- Seoul
Genuv Questions
Genuv's website is genuv.com
Genuv's LinkedIn profile is https://www.linkedin.com/company/genuv
Genuv has
12 employees.
View email and phone details for 12
employees at Genuv.
Genuv's industry is
Biotechnology
Genuv's top competitors are
Cluely,
Nexton,
Macrogen Inc.,
Allogene Therapeutics,
Curocell,
Innogi Technologies,
Plagen,
Scai Therapeutics,
Cutisbio,
Bioinfra Inc..
Genuv's categories are Biotechnology
Genuv's founding year is 2016
